– New investors include InVivium Capital, Franklin Templeton, Point72, Eli Lilly and Company, and Alexandria Venture Investments –– Funds will be used to support ongoing and planned late-stage clinical development of CNS product candidates with four Phase 2 readouts expected across the nex